Botulinum toxin may slightly reduce monthly migraine days but has higher discontinuation rates due to adverse events.

Bladder-intact disease-free survival was 60% 2 years posttreatment with pembrolizumab combined with gemcitabine-based chemoradiation.

Glucagon-like peptide-1 (GLP-1) receptor agonists may be a potential novel treatment for alcohol use disorder, according to a ...

It’s also not clear that HHS has the regulatory authority to enforce its threat without going through a formal rulemaking process, lawyers and dietitians say.

This marks a shift from years of aggressive regulation against flavored vapes after the FDA rejected marketing approvals for more than 1 million flavored products.

Treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease are under review.